Pulmatrix Past Earnings Performance
Past criteria checks 0/6
Pulmatrix has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 3.6% per year.
Key information
2.5%
Earnings growth rate
60.9%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 3.6% |
Return on equity | -78.5% |
Net Margin | -193.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100
Jul 12Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?
Feb 22Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?
Oct 29Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts
Aug 16Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 14We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate
May 27We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate
Feb 11Revenue & Expenses BreakdownBeta
How Pulmatrix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 7 | -14 | 7 | 0 |
30 Sep 23 | 7 | -16 | 7 | 0 |
30 Jun 23 | 7 | -18 | 7 | 0 |
31 Mar 23 | 6 | -18 | 7 | 0 |
31 Dec 22 | 6 | -19 | 7 | 0 |
30 Sep 22 | 5 | -22 | 7 | 0 |
30 Jun 22 | 4 | -25 | 7 | 0 |
31 Mar 22 | 5 | -24 | 7 | 0 |
31 Dec 21 | 5 | -23 | 6 | 0 |
30 Sep 21 | 7 | -19 | 6 | 16 |
30 Jun 21 | 10 | -21 | 6 | 16 |
31 Mar 21 | 11 | -19 | 6 | 16 |
31 Dec 20 | 13 | -19 | 7 | 16 |
30 Sep 20 | 12 | -20 | 7 | 0 |
30 Jun 20 | 9 | -13 | 7 | 0 |
31 Mar 20 | 11 | -20 | 9 | 0 |
31 Dec 19 | 8 | -21 | 8 | 0 |
30 Sep 19 | 6 | -21 | 8 | 0 |
30 Jun 19 | 5 | -22 | 8 | 0 |
31 Mar 19 | 0 | -20 | 7 | 0 |
31 Dec 18 | 0 | -21 | 8 | 0 |
30 Sep 18 | 0 | -21 | 8 | 0 |
30 Jun 18 | 0 | -20 | 8 | 0 |
31 Mar 18 | 0 | -20 | 8 | 0 |
31 Dec 17 | 0 | -18 | 8 | 0 |
30 Sep 17 | 0 | -23 | 8 | 0 |
30 Jun 17 | 0 | -22 | 7 | 0 |
31 Mar 17 | 0 | -26 | 7 | 0 |
31 Dec 16 | 1 | -28 | 8 | 0 |
30 Sep 16 | 1 | -23 | 8 | 0 |
30 Jun 16 | 2 | -24 | 9 | 0 |
31 Mar 16 | 1 | -30 | 10 | 0 |
31 Dec 15 | 1 | -26 | 10 | 0 |
30 Sep 15 | 1 | -6 | 8 | 0 |
30 Jun 15 | 1 | -13 | 6 | 0 |
31 Mar 15 | 0 | -5 | 4 | 0 |
31 Dec 14 | 0 | -6 | 3 | 0 |
31 Dec 13 | 1 | -13 | 3 | 0 |
Quality Earnings: PULM is currently unprofitable.
Growing Profit Margin: PULM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PULM is unprofitable, but has reduced losses over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare PULM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PULM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: PULM has a negative Return on Equity (-78.47%), as it is currently unprofitable.